Explore 3 Stock Ideas & Industry Insights Download Free Report

Spencer Pharmaceutical Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
250
Market Cap
0.00M

Momentum Score

…

Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Spencer Pharmaceutical Inc (OTC: SPPH) is a small publicly traded company identified in the pharmaceutical sector; public disclosures and filings are sparse. Long-term growth may depend on product development, licensing or commercialization and access to financing, so investors may find upside exposure to early-stage pharmaceutical assets but face high information uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
108.29%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2010-12-31 2009-12-31 2008-12-31
Type yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31
Income before tax -0.94M -0.94M 0.44M
Minority interest 0.00M 0.00M 0.00M
Net income -0.94M 0.00M 0.44M
Selling general administrative 0.94M 0.94M 0.94M
Gross profit 0.00M 0.00M 0.44M
Ebit -0.94M 0.00M 0.44M
Non operating income net other 0.00M 0.00M 0.00M
Operating income -0.94M -0.94M 0.44M
Other operating expenses 0.00M 0.00M 0.00M
Interest expense 0.00M 0.00M 0.00M
Extraordinary items 0.00M 0.00M 0.00M
Non recurring 0.00M 0.00M 0.00M
Other items 0.00M 0.00M 0.00M
Income tax expense 0.00M 0.00M 0.00M
Total revenue 0.00M 0.00M 0.44M
Total operating expenses 0.94M 0.00M 0.00M
Cost of revenue 0.00M 0.00M 0.00M
Total other income expense net 0.00M 0.00M 0.00M
Discontinued operations 0.00M 0.00M 0.00M
Net income from continuing ops -0.94M -0.94M 0.44M
Net income applicable to common shares -0.94M -0.94M 0.44M
Preferred stock and other adjustments 0.00M 0.00M 0.00M
Breakdown 2010-12-31 2009-12-31 2008-12-31
Type yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31
Total assets 0.77M 0.06M 0.00M
Intangible assets 0.32M 0.06M 0.00M
Other current assets 0.00M 0.00M 0.00M
Total liab 1.64M 0.06M 0.00M
Total stockholder equity -0.87M 0.00M 0.00M
Deferred long term liab 0.00M 0.00M 0.00M
Other current liab 0.00M 0.00M 0.00M
Common stock 0.27M 0.20M 0.01M
Retained earnings -18.00M -17.05M -17.05M
Other liab 0.00M 0.00M 0.00M
Good will 0.00M 0.00M 0.00M
Other assets 0.00M 0.00M 0.00M
Cash 0.46M 0.00M 0.00M
Total current liabilities 1.64M 0.06M 0.00M
Short term debt 0.00M 0.00M 0.00M
Short long term debt 2.91M 0.09M 0.00M
Other stockholder equity -0.09M -0.10M 2.46M
Property plant equipment 0.00M 0.00M 0.00M
Total current assets 0.46M 0.00M 0.00M
Long term investments 0.00M 0.00M 0.00M
Net tangible assets -1.19M -0.06M 0.00M
Short term investments 0.00M 0.00M 0.00M
Long term debt 0.00M 0.00M 0.00M
Inventory 0.00M 0.00M 0.00M
Accounts payable 0.47M 0.00M 0.00M
Total permanent equity 0.00M 0.00M 0.00M
Noncontrolling interest in consolidated entity 0.00M 0.00M 0.00M
Temporary equity redeemable noncontrolling interests 0.00M 0.00M 0.00M
Accumulated other comprehensive income 0.00M 0.00M 0.00M
Additional paid in capital 0.00M 0.00M 0.00M
Common stock total equity 0.00M 0.00M 0.00M
Preferred stock total equity 0.00M 0.00M 0.00M
Retained earnings total equity 0.00M 0.00M 0.00M
Treasury stock 0.00M 0.00M 0.00M
Accumulated amortization 0.00M 0.00M 0.00M
Non currrent assets other 0.00M 0.00M 0.00M
Deferred long term asset charges 0.00M 0.00M 0.00M
Non current assets total 0.00M 0.00M 0.00M
Capital lease obligations 0.00M 0.00M 0.00M
Long term debt total 0.00M 0.00M 0.00M
Breakdown 2010-12-31 2009-12-31 2008-12-31
Type yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31
Investments 0.00M 0.00M 0.00M
Change to liabilities 0.00M 0.00M 0.00M
Total cashflows from investing activities -0.26M -0.06M -0.06M
Net borrowings 0.00M 0.00M 0.00M
Total cash from financing activities 0.07M 0.07M 0.07M
Change to operating activities 1.59M 0.06M -0.44M
Net income -0.94M 0.00M 0.44M
Change in cash 0.46M 0.46M -0.00M
Total cash from operating activities 0.64M 0.06M -0.00M
Depreciation 0.00M 0.00M 0.00M
Other cashflows from investing activities 0.00M 0.00M 0.00M
Dividends paid 0.00M 0.00M 0.00M
Change to inventory 0.00M 0.00M 0.00M
Change to account receivables 0.00M 0.00M 0.00M
Sale purchase of stock 0.17M 4.08M 0.66M
Other cashflows from financing activities 0.00M -2.55M -2.55M
Change to netincome 0.00M 0.00M 0.00M
Capital expenditures 0.00M 0.00M 0.00M
Change receivables 0.00M 0.00M 0.00M
Cash flows other operating 0.00M 0.00M 0.00M
Exchange rate changes 0.00M 0.00M 0.00M
Cash and cash equivalents changes 0.00M 0.00M 0.00M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
SPPH
Spencer Pharmaceutical Inc
-
-%
0.00 - - - -
DOGEF
Orsted A/S
-
-%
20.13 28.82 0.66 6.50 0.07
TBB
AT&T Inc. 5.35% GLB NTS 66
0.12
0.70%
17.72 4.60 - - -
CCZ
Comcast Holdings Corp
-
-%
62.32 55.07 - - -
STMZF
Scottish Mortgage Investment Trust PLC
-1.09
5.69%
18.00 - - 2.56 -

Profile*

Spencer Pharmaceutical Inc

Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.

8 Faneuil Hall Marketplace, Boston, MA, United States, 02109

617-973-5017

Name Title Year Born
Dr. Maximilien Arella Chairman, Chief Exec. Officer and Pres 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…